Transgenomic licenses exclusive rights to multiplexed ICE COLD-PCR technology Transgenomic announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology. The new license is exclusive to Transgenomic and expands the current relationship with Dana-Farber. It covers all fields and applications of the multiplexed technology, which makes possible the simultaneous detection of multiple DNA mutations from a single liquid sample, such as blood or urine.
Transgenomic launches ICE-COLD PCR service in biomarket identification business Transgenomic announced that its groundbreaking Multiplexed ICE COLD PCR technology is now available to pharmaceutical and biotechnology customers of the company’s Biomarker Identification business unit. MX-ICP is an ultra-high sensitivity DNA amplification technology that allows the detection of multiple mutations in multiple genes from any sample, either from a tumor biopsy or from liquids such as blood or urine. MX-ICP is validated and available for use on all sequencing platforms.